Table 1.

Prior bacterial discoveries associated with Roseburia intestinalis.

Study	Nationality	Year	Journal	Findings
(Duncan et al., 2002)	UK	2002	IJSEM	Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human feces.
(Hold et al., 2003)	UK	2003	A.E.M	Roseburia intestinalis: 2.3% of fecal microbiota populations at mean. The genus Roseburia is among the most abundant known butyrate-producing bacteria in human feces.
(Duncan et al., 2004)	UK	2004	A.E.M	Roseburia spp. seem to have a consistent contribution for acetate to butyrate formation.
(Mirande et al., 2010)	France	2009	J Appl Microbiol	Roseburia intestinalis is a dominant xylanolytic bacterium in dietary fiber degradation and fermentation.
(Van den Abbeele et al., 2013)	Belgium	2012	ISME J	Roseburia intestinalis colonizes mucins most specifically with flagella and may allow for penetration into the mucus layer.
(Martinez et al., 2013)	USA	2012	ISME J	Whole-grain barley enriches Roseburia intestinalis and improves metabolic dysfunctions.
(Qin et al., 2012)	China	2012	Nature	Roseburia intestinalis is one of the markers that might be useful for classifying type 2 diabetes.
(Russell et al., 2013)	UK	2013	MNFR	Roseburia intestinalis can ferment tryptophan indole-3-carboxylic acid.
(Arpaia et al., 2013)	USA	2013	Nature	Butyrate from colonic microorganisms promotes the differentiation of Tregs and influences the pro- and anti-inflammatory balance.
(Dostal et al., 2015)	Switzerland	2015	J Nutr	Iron modulates butyrate production in Roseburia intestinalis.
(Hoffmann et al., 2016)	France	2016	ISME J	Roseburia intestinalis induced a decreased IFNγ and IL-17 production with increased IL-22 production.
(Hegazy et al., 2017)	UK	2017	Gastroenterology	Roseburia intestinalis reactive CD4+ T cells support intestinal homeostasis, and their function is altered during inflammation.
(Kasahara et al., 2018)	USA	2018	Nat Microbial	Roseburia intestinalis interacts with dietary plant polysaccharides to provide protection against atherosclerosis.
(Shen et al., 2018)	China	2018	JGH	Roseburia intestinalis alleviates experimental colitis pathology by inducing anti-inflammatory responses.
(Quan et al., 2018)	China	2018	BBRC	Roseburia intestinalis-derived flagellin is a negative regulator of intestinal inflammation.
(Zhu C. et al., 2018)	China	2018	Mol Med Rep	Roseburia intestinalis inhibits interleukin-17 excretion and promotes regulatory T-cell differentiation.
(Seo et al., 2020)	Korea	2019	Cell Host Microbe	Roseburia intestinalis improves the gut ecosystem, leading to ameliorated alcoholic fatty livers.
(Tan et al., 2019)	China	2019	Scandinavian J.G	Roseburia intestinalis inhibits oncostatin M and maintains tight junction integrity in a murine model.
(Luo et al., 2019)	China	2019	Mol Med Rep	Roseburia intestinalis supernatant ameliorates colitis induced in mice by regulating the immune response.
(La Rosa et al., 2019)	Norway	2019	Nat Com	Roseburia intestinalis is a primary degrader of dietary β-mannans.
(Ruff et al., 2019)	USA	2019	Cell Host Microbe	Roseburia intestinalis cross-reacts with T and B cells to induce auto-APS antibody.
(Kellermayer, 2019)	USA	2019	Gastroenterology	Roseburia species: prime candidates for microbial therapeutics in inflammatory bowel disease.
(Xu et al., 2021)	China	2021	Therap Adv Gastroenterol	Roseburia intestinalis modulates the gut homeostasis by the gut–brain axis.
(Montalban-Arques et al., 2021)	Switzerland	2021	Cell Host Microbe	Roseburia intestinalis exerts synergic therapeutical effects in anti-PD-1 therapy of colorectal cancer.